A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System Lymphoma
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Orelabrutinib (Primary) ; Pemetrexed (Primary)
- Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
- Focus Therapeutic Use
Most Recent Events
- 23 Apr 2025 Planned primary completion date changed from 21 Dec 2024 to 30 Jun 2025.
- 02 Feb 2022 New trial record
- 28 Jan 2022 Planned End Date changed from 1 Feb 2027 to 21 Dec 2026.